NCT03633006 is a clinical trial of Blood Sample Collection in Lung Cancer (Diagnosis), sponsored by Exact Sciences Corporation.

Who is sponsoring NCT03633006?

NCT03633006 is sponsored by Exact Sciences Corporation.

What drugs are being tested in NCT03633006?

Interventions in NCT03633006: Blood Sample Collection, Blood Sample Collection, Blood Sample Collection.

What condition does NCT03633006 study?

NCT03633006 studies Lung Cancer (Diagnosis).

Is NCT03633006 still recruiting?

NCT03633006 is currently completed. Last updated 15 February 2021.

Last reviewed 2021-02-15 · How we verify

NCT03633006

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer

Completed Last updated 15 February 2021

What this trial tests

trial testing Blood Sample Collection in Lung Cancer (Diagnosis) in 3,298 participants. Completed in 31 December 2020.

Timeline

11 April 2016

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Exact Sciences Corporation
Status	Completed
Study type	OBSERVATIONAL
Enrollment	3,298
Start date	11 April 2016
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	83 locations across United States

Drugs / interventions tested

Blood Sample Collection — full drug profile →
Blood Sample Collection — full drug profile →
Blood Sample Collection — full drug profile →

Conditions studied

Lung Cancer (Diagnosis) — all drugs for Lung Cancer (Diagnosis) →

Sponsor

Exact Sciences Corporation

Who can join

35 and older, any sex, with Lung Cancer (Diagnosis). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens for use in assessing new biomarkers for the detection of neoplasms of the lung. Subjects will be men and women, 35 years of age and older, with a CT confirmed nodule measuring 6-30 mm.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review.
Garbo E, Del Rio B, Ferrari G, Cani M, et al · · 2023 · cited 11× · PMID 37835468 · DOI 10.3390/cancers15194774

Verify or expand the search:

Other trials of Blood Sample Collection

Trials testing the same drug.

NCT07436637 — Guardant Shield Colorectal Cancer Screening · NA · not yet recruiting
NCT07054346 — Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 · Phase 1 · recruiting
NCT06695494 — Enabling Genomic Testing in Cancer of Unknown Primary · recruiting
NCT07405515 — Pathophysiology of Dysautonomia and Postural Tachycardia Syndrome (POTS) in Post-viral Syndromes and COVID-19 · NA · active not recruiting
NCT05487248 — A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients · NA · active not recruiting

Other recruiting trials for Lung Cancer (Diagnosis)

Currently open trials in the same condition.

NCT07168993 — Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Di · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07510724 — Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab · recruiting
NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
NCT07241182 — Antrodia Cinnamomea Extract Effects on Lung Cancer Patients' Quality of Life During Chemotherapy · NA · recruiting

Other Exact Sciences Corporation trials

Trials by the same sponsor.

NCT05246839 — Informed Choice - Compass · terminated
NCT05210283 — CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer · active not recruiting
NCT04473625 — Stool Collection Sub-Study of Exact Sciences Protocol 2018-01 · completed
NCT04395391 — Home Usability Study of the SARS-CoV-2 (COVID-19) Test · completed
NCT04213326 — Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03633006 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Exact Sciences Corporation
Last refreshed: 15 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03633006.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing